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| CLASSICAL HEMOSTASIS-BALANCING PLATELET ADHESIVENESS IN CIRCULATION AND AT THE VASCULAR INTERFACE
Platelets are critical for the body's response to vascular injury. To form a hemostatic plug, they rely on a signal transduction machinery, which is optimized to sense and respond to minor changes in the environment, and to mediate a near-immediate conversion of cell-surface integrins from an anti-adhesive to a pro-adhesive state. While patrolling the vasculature, however, platelet activation has to be prevented in order to avoid thrombocytopenia and/or thrombosis. In this first section of our review, we will discuss the exquisite balance between activating and inhibitory mechanisms that control platelet adhesiveness in the circulation and at sites of vascular injury.
To efficiently plug a vascular lesion and prevent blood loss into the surrounding tissue, platelets have evolved highly specialized adhesion mechanisms, which enable cell-matrix and cell-cell interactions in the presence of fluid shear stress. Initial platelet recruitment at sites of vascular injury is mediated by glycoprotein (GP) Ib-V-IX
Essentials
• Part 1 of this review summarizes recent findings on the exquisite balance between activating and inhibitory mechanisms that control platelet adhesiveness in the circulation and at sites of vascular injury.
• Part 2 of this review discusses molecular differences and similarities for how platelets secure vascular integrity at sites of inflammation and at sites of mechanical trauma. complex binding to von Willebrand factor (VWF). This interaction has a sufficiently fast association rate to enable platelet capture even at very high shear rates, but it supports only transient adhesion. Thus, it serves the purpose of decelerating platelets in the proximity of the lesion, and allow enough time for the platelets to become activated and engage more stable adhesive interactions. ISTH conference suggests that altered cytoskeletal dynamics may result in dysregulated integrin activation. [8] [9] [10] Active β1 integrins (α2β1, α6β1, α5β1) support adhesion to the ECM for the first platelet layer, which then becomes a new reactive surface for further platelet deposition. Active αIIbβ3 integrins, which are extremely abundant on the platelet surface, bind multivalent plasma proteins (eg, fibrinogen or VWF) that bridge adjacent activated platelets and thus support platelet-platelet cohesion. 11, 12 The main signals that drive the three-dimensional growth of the hemostatic plug are soluble agonists (Figure 1) 
but it also internalizes more slowly and thus generates a steady and sustained integrin activation signal. [16] [17] [18] Similarly, the ADP receptor P2Y1, which is not very abundant on the platelet surface, 19 is rapidly desensitized. 20, 21 Thus, it can only cause a rapid but short-lived rise of the cytosolic calcium concentration and needs co-signaling through the P2Y12 receptor to support platelet aggregation. 22, 23 So both PAR1
and P2Y1 are very sensitive and provide a fast but reversible activation response, while PAR4 and P2Y12 are required to sustain the signal. As only the stimulation of both receptors provides an integrated response that is both rapid and sustained, this provides an elegant mechanism to limit thrombus growth in the outer layers of the thrombus, where agonist concentrations diminish. While it is not the major player in classical hemostasis, ITAM signaling is critical for another form of hemostasis that is responsible for maintaining vascular integrity at sites of inflammation 40 (see next section).
Most GPCRs and ITAM-coupled receptors induce the activation of phospholipase C (PLC), a key enzyme in the generation of the second messengers, calcium and diacylglycerol. At this ISTH meeting, we presented definitive evidence that the small GTPase RAP1 is the main signaling node that integrates these second messenger signals with integrin activation. 41 Previous studies in other cells [42] [43] [44] [45] and in heterologous cell lines expressing αIIbβ3 46 suggested that RAP1 controls integrin conversion to a high affinity state by recruiting TALIN to the plasma membrane. However, platelets lacking the most abundant RAP isoform, RAP1B, only displayed a partial integrin activation defect. 47 Since systemic deficiency of the closely related isoform, RAP1A was reported to have no effect on platelet aggregation (unpublished observation 47 ), this led to the wrong belief that there is a powerful RAP1-independent signaling pathway that can mediate integrin activation in platelets. 48 Employing mice where Rap1a and/or Rap1b were conditionally deleted in the megakaryocyte/platelet lineage, we have produced preliminary data (presented at the ISTH meeting) supporting a role for both RAP1A and RAP1B in platelet integrin activation. 41 When comparing the Rap1a/b-double deficient mice to Talin1-deficient mice,
we found that there is very limited integrin activation, mediated by TALIN1, in platelets lacking both RAP1 isoforms. Importantly, this residual RAP1-indendent integrin activation can only support slow and sub-maximal aggregation in vitro, while it was not sufficient to support hemostatic plug formation in vivo. 41 Thus, the RAP1/TALIN signaling axis is critical in platelet integrin activation and classical hemostasis.
There is a very rational explanation for why RAP1A and RAP1B
are critical in hemostatic plug formation. RAP GTPases, like the heterotrimeric G proteins, are molecular switches that can be turned on rapidly by GEF-mediated GTP for GDP exchange. The main RAP-GEF in platelets is CalDAG-GEFI, a multidomain protein predominantly found in blood cells. 49 For firm platelet adhesion to occur, RASA3 activity has to be downmodulated. Critical for the down-modulation of Rasa3 activity is signaling via the Gi-coupled receptor for ADP, P2Y12. 61 Thus, similar to the GPCR dual receptor systems, RAP activation is a two-step process.
A rapid but reversible activation step, mediated by calcium/CalDAG-GEFI signaling, is followed by a second step, RASA3 inactivation, that is required to sustain the signal. Again, this two-step system is important to facilitate controlled platelet adhesion and thrombus growth under high shear stress conditions.
What is special about the RAP1 signaling pathway, however, is how tightly controlled it has to be in order to avoid serious complica- ). Given these numbers, it can be concluded that (i) only minimal changes in cytosolic calcium are required to mount a robust CalDAG-GEFI response, and (ii) that some CalDAG-GEFI protein exists in an active conformation even in circulating, quiescent platelets.
Consistent with these conclusions, complete CalDAG-GEFI deficiency is ill tolerated as it causes moderate to severe bleeding in humans and mice. 51, [53] [54] [55] [58] [59] [60] At the same time, CalDAG-GEFI/RAP1 signaling has to be restrained by RASA3 in circulating platelets to avoid severe thrombocytopenia and blood-lymphatic mixing in the developing embryo. Together, these specialized mechanisms ensure the tight regulation of platelet adhesiveness, which is crucial for the platelets' ability to efficiently form a stable and self-limiting hemostatic plug at sites of vascular injury. However, platelets are also important for the maintenance of vascular integrity at sites of inflammation, 62 where a different platelet response is required to seal small gaps in the endothelial lining.
| VASCULAR INTEGRITY VS HEMOSTATIC PLUG FORMATION-LESIONS OF DIFFERENT SIZE REQUIRE UNIQUE PLATELET RESPONSES
As outlined above, platelet function during hemostatic plug formation depends strongly on G protein signaling. Hemostatic plugs are aggregates of platelets, where only few of these cells make direct contact with the ECM in the damaged vascular wall ( Figure 1A ).
GPCRs sense soluble agonists that diffuse into the lesion, and they tiny lesions induced by transmigrating inflammatory cells. 64 Without platelets (severe thrombocytopenia), these vessels become leaky for RBCs, causing hemorrhage in the affected areas. 62 We have recently demonstrated that GPCRs are not critical for platelet function in this setting. 40, 65 Instead, vascular integrity at sites of inflammation depends strongly on platelet ITAM signaling, mediated by GPVI and CLEC-2. This ISTH meeting provided important new information on the molecular mechanisms underlying this unique form of hemostasis. In our ongoing studies, we observed that mice lacking both RAP1
isoforms, RAP1A and RAP1B, do not bleed at sites of inflammation, even though classical hemostasis is strongly impaired in these mice. 41 Our findings of significant bleeding at sites of inflammation in the skin (reverse passive Arthus reaction) of Talin1-deficient mice, however, do suggest that platelet integrin signaling is critical in the prevention of inflammatory hemorrhage. There are several questions that arise from these observations. For example, why do we observe inflammatory bleeding in Talin1-deficient mice while no such bleeding was observed in mice lacking αIIbβ3
62
? Like GPCRs, αIIbβ3 is particularly important for platelet-platelet aggregate formation. The adhesion to the ECM, however, can also be mediated by β1 integrins, such as α2β1
(collagen) and α6β1 (laminin). Thus, it is likely that a redundancy between β3 and β1 integrins in mediating platelet adhesion to the ECM protects β3-deficient mice from inflammatory hemorrhage, a hypothesis that warrants further investigation. Another important question is why Rap1-deficiency does not cause inflammatory hemorrhage like Talin1-deficiency, while both RAP1 and TALIN1 are critical for classical hemostasis? Our preliminary studies presented at the ISTH conference show that platelets lacking RAP1A and RAP1B retain a weak but significant ability to activate integrins in response to agonist stimulation. 41 The resulting slow aggregation response observed in vitro, however, is not sufficient for hemostatic plug formation at sites of mechanical injury. 41 How RAP1-deficient platelets manage to prevent inflammatory hemorrhage is currently not clear. A likely explanation is that shear stress is less of a factor in this situation as platelets may simply get trapped in the ECM ( Figure 1B ). If that is the case then the delay in integrin activation in Rap1-deficient platelets would be negated by this trapping mechanism, which retains platelets in the EC gaps long enough for integrins to get engaged.
Our preliminary studies also demonstrate that inflammatory hemorrhage is significantly less severe in Talin1-deficient mice when compared to thrombocytopenic mice. 41 This, of course, begs the question about the nature of this TALIN (maybe integrin)-independent contribution of platelets to vascular integrity in inflammation. One potential explanation that was brought forward at the ISTH meeting is that CLEC2, the hemITAM signaling receptor critical in this response, may serve as an adhesion receptor in addition to its function in platelet activation. As outlined in the abstract by Haining et al., studies in mice expressing a signaling defective mutant of CLEC2 (Y7A KI) suggest a signaling-independent contribution of the CLEC2 ectodomain to thrombus stability 38, 39 A similar signalingindependent, adhesive role was also reported for GPVI. 36, 37 Another interesting study on this topic was presented at ISTH 2017 by Rayes et al., who demonstrated that podoplanin, the ligand for CLEC2, is found in the deeper layers of the vasculature. 66 The authors suggest that the CLEC2-podoplanin interaction is required as a fail-safe in case GPVI is malfunctional, a hypothesis that is supported by the observation that megakaryocyte/platelet-specific deletion of CLEC2 in mice does not cause increased inflammatory hemorrhage, unless the mice are crossed with GPVI-deficient mice. 66 Interestingly, the preliminary studies by Rayes et al. also suggest that platelets contribute to vascular integrity in LPS challenged lungs by a GPVI/CLEC2-independent but GPIbα-dependent mechanism, findings that are in conflict with previous findings. 40 Additional studies are required to clarify whether there is indeed an organ and/or inflammatory triggerspecific platelet response in this form of hemostasis.
Release of vasoactive substances from platelet granules has been proposed as another, TALIN-independent, contribution of platelets to vascular integrity in inflammation. 67, 68 However, elegant studies by 
| CONCLUSIONS
Decades of research have uncovered many of the molecular mechanisms underlying platelet activation and adhesion at sites of vascular injury. In this review, we provide an overview of the main regulatory mechanisms controlling platelet reactivity, both in circulation and at the vascular interface. We also discuss the latest developments in this field, presented at this year's ISTH meeting. These studies provide critical new information on the platelet signaling machinery, filling gaps but also challenging our current thinking of how platelets work. We are excited to see whether the many important scientific questions raised by these studies can be answered in time for presentation at the next ISTH meeting. 
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